|Bid||2.0300 x 1000|
|Ask||2.1100 x 900|
|Day's Range||1.9500 - 2.2500|
|52 Week Range||1.9500 - 16.8610|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.86|
OXFORD, United Kingdom and CAMBRIDGE, Mass., Aug. 06, 2018-- Summit Therapeutics plc announces that Glyn Edwards, Chief Executive Officer, will present at the Canaccord Genuity Growth Conference on 9 August ...
Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces today the publication in the journal PLOS ONE of microbiome analyses highlighting ridinilazole as a precision antibiotic in development for the treatment of C. difficile infection (‘CDI’). The clinical management of CDI is stymied by poor sustained cures due to high recurrence rates after initial infection. In a double-blind Phase 2 clinical trial, ridinilazole was highly preserving of patients’ microbiomes compared to patients treated with the broad-spectrum standard of care antibiotic vancomycin.
WASHINGTON , July 30, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Summit Therapeutics plc (NASDAQ: SMMT; AIM: SUMM) (Summit) to its coalition of companies ...
CARB-X's $4.5 million award comes just a few weeks after the company shut down on a Duchenne muscular dystrophy trial and laid off most of their employees in Cambridge.
Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces it has been awarded up to $4.5 million from CARB-X, a public-private partnership devoted to accelerating early antibiotic research and development. This award will be used to support Summit’s wholly-owned, lead series of new mechanism antibiotic compounds for gonorrhoea. Gonorrhoea is recognised as an urgent bacterial threat by the US Centers for Disease Control (‘CDC’) due to the diminishing treatment arsenal.
NEW YORK, NY / ACCESSWIRE / June 28, 2018 / Aquinox Pharmaceuticals and Summit Therapeutics both saw their shares dramatically drop on Wednesday after each company announced failed trial results. Aquinox Pharmaceuticals, Inc. shares closed down almost 85% on Wednesday and hit a new low of $2.25 on about 14.2 million shares traded. The company revealed that late-stage trial results for its bladder pain drug failed to perform better than the placebo in patients.
Summit Therapeutics plc (SUMM.L) (SMMT) today announces PhaseOut DMD has not met its primary or secondary endpoints after 48 weeks of treatment of ezutromid in patients with Duchenne muscular dystrophy (‘DMD’). PhaseOut DMD was a multi-centre, open-label Phase 2 clinical trial of the utrophin modulator, ezutromid. Based on this outcome, the Company is discontinuing its development of ezutromid and as a result, will be implementing cost reduction measures.
Oxford, June 15, 2018-- Oxford, UK, and Cambridge, MA, US, 15 June 2018– Summit Therapeutics plc announces that Glyn Edwards, Chief Executive Officer, will present at the JMP Securities Life Sciences Conference ...
Summit Therapeutics plc (SMMT) (SUMM.L) announces the discovery of a second novel target to kill the bacteria Neisseria gonorrhoeae. The new target, identified using Summit’s Discuva Platform, is distinct from that of existing antibiotics and also from Summit’s recently announced lead series of new mechanism antibiotics for gonorrhoea. Summit also reports the discovery of a promising new series of compounds against this second target.
NEW YORK, June 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Summit ...
OXFORD, United Kingdom and CAMBRIDGE, Mass., June 05, 2018-- Summit Therapeutics plc today reports its financial results for the first quarter ended 30 April 2018 and provides an update on operational ...
OXFORD, United Kingdom and CAMBRIDGE, Mass., June 01, 2018-- Summit Therapeutics plc will announce its financial results for the first quarter ended 30 April 2018 on 5 June 2018.. About Summit Therapeutics ...